Jason Luke, MD, FACP, UPMC Hillman Cancer Center, Pittsburgh, PA, comments on updated results from the Phase III KEYNOTE-716 trial (NCT03553836) of adjuvant pembrolizumab in patients with resected stage IIB/IIC melanoma. Pembrolizumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) compared to placebo, with a median follow-up of four years. A promising recurrence-free survival 2 (PRFS2) was additionally reported. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
